Skip to main content
. 2021 May;11(5):1710–1722. doi: 10.21037/qims-20-840

Table 2. Comparison of baseline GGN data between derivation set and verification set.

Index Total (n=197) Derivation set (n=97) Verification set (n=100) P value
Age (years) 60.1±9.0 60.8±8.2 59.4±9.8 0.309
Sex 0.543
   Female 132 (67.0) 67 (69.1) 65 (65.0)
   Male 65 (33.0) 30 (30.9) 35 (35.0)
Smoking history 38 (19.3) 18 (18.6) 20 (20.0) 0.797
Multifocality 84 (42.6) 44 (45.4) 40 (40.0) 0.447
Nodule type 0.649
   pGGN 68 (34.5) 35 (36.1) 33 (33.0)
   mGGN 129 (65.5) 62 (63.9) 67 (67.0)
Location 0.768
   Peripheral 188 (95.4) 93 (95.9) 95 (95.0)
   Center 9 (4.6) 4 (4.1) 5 (5.0)
Shape 0.540
   Round/oval 116 (58.9) 55 (56.7) 61 (61.0)
   Irregular 81 (41.1) 42 (43.3) 39 (39.0)
Margin 0.925
   Smooth 109 (55.3) 54 (55.7) 55 (55.0)
   Lobulated 88 (44.7) 43 (44.3) 45 (45.0)
Bronchial sign 144 (73.1) 66 (68.0) 78 (78.0) 0.115
Vacuole sign 32 (16.2) 17 (17.5) 15 (15.0) 0.631
Pleural indentation 113 (57.4) 55 (56.7) 58 (58.0) 0.854
Vessel convergence sign 184 (93.4) 91 (93.8) 93 (93.0) 0.818
DGGN (mm) 19.1 (13.4–25.0) 18.0 (12.9–24.8) 20.8 (14.1–25.3) 0.131
Dsolid (mm) 5.8 (0.0–12.0) 5.7 (0.0–12.0) 5.9 (0.0–12.0) 0.915
CTR 0.3 (0.0–0.6) 0.4 (0.0–0.6) 0.3 (0.0–0.6) 0.648
CTGGO (HU) −451.0 (−562.0 to −368.0) −444.0 (–572.0 to −368.0) −457.0 (−558.8 to −376.8) 0.977
ΔCTGGO-LP (HU) 413.0 (305.0–490.0) 420.0 (305.0–499.0) 408.5 (309.0–479.8) 0.777
SUVmax 2.2 (1.2–3.3) 2.2 (1.1–3.4) 2.2 (1.2–3.2) 0.916
SUVindex 0.9 (0.5–1.4) 0.8 (0.4–1.4) 0.9 (0.5–1.3) 0.686
Pathology 0.982
   Benign* 27 (13.7) 13 (13.4) 14 (14.0)
   Preinvasive-MIA 27 (13.7) 13 (13.4) 14 (14.0)
   IAC 143 (72.6) 71 (73.2) 72 (72.0)

Data were presented as mean ± SD/P50 (P25–P75)/N (%). GGN, ground-glass nodule; pGGN, pure GGN; mGGN, mixed GGN; DGGN, diameter of the GGN; Dsolid, diameter of the solid component; CTR, the ratio of Dsolid to DGGN; CTGGO, attenuation value of the GGO component on CT; ΔCTGGO-LP, the difference between CTGGO and CTLP; SUVmax, maximum standardized uptake value; SUVindex, ratio of the nodule SUVmax to liver SUVmean; MIA, microinvasive adenocarcinoma; IAC, invasive adenocarcinomas; GGO, ground-glass opacity; LP, lung parenchyma. *, benign GGNs were defined as either pathologic examination of tissue obtained via surgery or GGNs resolving during follow-up.